Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes
24/08/2026 12:11
BRIEF-Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes Aug 24 (Reuters) - Biomea Fusion, Inc. BMEA.O:
BIOMEA FUSION ANNOUNCES COMPLETION OF ENROLLMENT IN COVALENT-211 PHASE II TRIAL OF ICOVAMENIB IN INSULIN-DEFICIENT TYPE 2 DIABETES
BIOMEA FUSION, - TOPLINE 26-WEEK PRIMARY ENDPOINT DATA FROM COVALENT-211 EXPECTED IN Q1 2027
Source text: ID:nGNX6txzk7
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes